tartrate de zolpidem 5 mg - Výsledky vyhledávání

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

zolpidem-lupin zolpidem tartrate 10 mg tablet blister pack

lupin australia pty limited - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; hypromellose; magnesium stearate; titanium dioxide; macrogol 400 - zolpidem tartrate is indicated for the short term treatment of insomnia in adults (see dosage and administration).

Spojené státy - angličtina - NLM (National Library of Medicine)

zolpidem tartrate- zolpidem tartrate tablet for oral use - civ

invagen pharmaceuticals inc., - zolpidem tartrate (unii: wy6w63843k) (zolpidem - unii:7k383oqi23) - tablet - 5 mg - zolpidem tartrate tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. zolpidem tartrate tablets have been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see clinical studies (14)] . the clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. zolpidem tartrate tablets are contraindicated in patients with known hypersensitivity to zolpidem tartrate or to any of the inactive ingredients in the formulation. (also see section 5.2 severe anaphylactic and anaphyalctoid reactions) zolpidem tartrate was administered to pregnant sprague-dawley rats by oral gavage during the period of organogenesis at doses of 4, 20, or 100 mg based/kg/day. adverse maternal and embryo/fetal effects occurred at doses of 20 mg base/kg and higher, manifesting as dose-related lethargy and ataxia in pregnant rats while examination of fetal

Spojené státy - angličtina - NLM (National Library of Medicine)

zolpidem tartrate tablet, extended release

bryant ranch prepack - zolpidem tartrate (unii: wy6w63843k) (zolpidem - unii:7k383oqi23) - zolpidem tartrate 6.25 mg - zolpidem tartrate extended-release tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). the clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see clinical studies ( 14)]. zolpidem tartrate extended-release tablets are contraindicated in patients - who have experienced complex sleep behaviors after taking zolpidem tartrate extended-release [see warnings and precautions ( 5.1)]. - with known hypersensitivity to zolpidem. observed reactions include anaphylaxis and angioedema [see warnings and precautions ( 5.4 )]. risk summary neonates born to mothers using zolpidem late in the third trimester of pregnancy ha

Spojené státy - angličtina - NLM (National Library of Medicine)

zolpidem tartrate tablet, extended release

bryant ranch prepack - zolpidem tartrate (unii: wy6w63843k) (zolpidem - unii:7k383oqi23) - zolpidem tartrate 12.5 mg - zolpidem tartrate extended-release tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). the clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see clinical studies (14)]. zolpidem tartrate extended-release tablets are contraindicated in patients risk summary neonates born to mothers using zolpidem late in the third trimester of pregnancy have been reported to experience symptoms of respiratory depression and sedation [see clinical considerations and data]. published data on the use of zolpidem during pregnancy have not reported a clear association with zolpidem and major birth defects [see data]. oral administration of zolpidem to pregnant rats and rabbits did not indicate a risk for adverse effec